专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006040182A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的异种化合物
公开(公告)号：WO2006040182A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011106
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe , BACKFISCH, Gisela , BEYERBACH, Armin , LUBISCH, Wilfried
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe , BACKFISCH, Gisela , BEYERBACH, Armin , LUBISCH, Wilfried
IPC分类号： C07D207/09 , C07D401/12 , C07D405/12 , C07D409/12 , C07D401/04 , C07D403/04 , C07D413/12 , C07D205/04 , C07D413/10 , C07D413/14 , C07D211/28 , A61K31/397 , A61K31/445 , A61P25/16
CPC分类号： C07D413/14 , C07D205/04 , C07D207/09 , C07D211/28 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12
摘要： The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C,-C 6 -alkyl, C,-C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C l -C 6 -hydroxyalkyl, fluorinated C,-C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中n为0,1或2; G是CH

2. 发明申请

WO2006058753A1 TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节症状的三唑化合物
公开(公告)号：WO2006058753A1
公开(公告)日：2006-06-08
申请号：PCT/EP2005/012856
申请日：2005-12-01
申请人： ABBOTT GMBH & CO. KG , UNGER, Liliane , HAUPT, Andreas , BEYERBACH, Armin , DRESCHER, Karla , BRAJE, Wilfried , DARBYSHIRE, John , TURNER, Sean, C. , BACKFISCH, Gisela
发明人： UNGER, Liliane , HAUPT, Andreas , BEYERBACH, Armin , DRESCHER, Karla , BRAJE, Wilfried , DARBYSHIRE, John , TURNER, Sean, C. , BACKFISCH, Gisela
IPC分类号： A61K31/506 , C07D403/12 , A61P25/18
CPC分类号： C07D403/12
摘要： The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R 1 on the remaining carbon atom and a radical R 1a on one of the nitrogen atoms; R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxymethyl, fluorinated C 1 -C 6 alkyl, fluorinated C 3 -C 6 cycloalkyl, fluorinated C 1 -C 4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R 1a is hydrogen or C 1 -C 4 alkyl; and R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 6 alkyl or fluorinated C 3 -C 6 cycloalkyl; and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceuticaly composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one traizole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.
摘要翻译：本发明涉及式（I）化合物，其中n是1或2，Ar是在剩余的碳原子上带有自由基R 1的C结合的1,2,4-三唑基和其中一个氮原子上的基团R 1a; R 1是氢，C 1 -C 6烷基，C 3 -C 6烷基，C 1 -C 6烷基，C 1 -C 6烷基，氟化C 1 -C 6烷基，氟化C 1 -C 6烷基，C 1 -C 6烷基，C 1 -C 6烷基，氟化C 1 -C 4烷氧基甲基或任选取代的苯基或5-或6位的C 1 -C 6烷基，杂芳基; R 1a是氢或C 1 -C 4烷基; R 2是C 1 -C 6烷基，C 3 -C 6烷基，C 3 -C 6烷基，C 3 -C 6烷基，C 3 -C 6烷基，氟化C 1 -C 6烷基或氟化C 3 -C 6环烷基; 以及该化合物的生理耐受酸加成盐。本发明还涉及包含至少一种式（I）的三唑化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D 3受体拮抗剂或多巴胺D 3激动剂，所述方法包括给受试者施用有效量的式（I）化合物或生理学耐受的酸加成盐，需要。

3. 发明申请

WO2004089905A1 N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译： N - [（PIPERAZINYL）HETARYL]具有多巴胺D3受体亲和性的芳香酰胺化合物
公开(公告)号：WO2004089905A1
公开(公告)日：2004-10-21
申请号：PCT/EP2004/003872
申请日：2004-04-13
申请人： ABBOTT GMBH & CO. KG , BRAJE, Wilfried , HAUPT, Andreas , LUBISCH, Wilfried , GRANDEL, Roland , DRESCHER, Karla , GENESTE, Hervé , UNGER, Liliane , SAUER, Daryl, R. , TURNER, Sean, C.
发明人： BRAJE, Wilfried , HAUPT, Andreas , LUBISCH, Wilfried , GRANDEL, Roland , DRESCHER, Karla , GENESTE, Hervé , UNGER, Liliane , SAUER, Daryl, R. , TURNER, Sean, C.
IPC分类号： C07D213/76
CPC分类号： C07D213/74 , C07D213/76 , C07D239/48 , C07D239/50 , C07D403/04 , C07D403/14 , C07D487/08
摘要： The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I ) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R a which is/are selected, independently of each other, from halogen, CN, NO 2 , C0 2 R 4 , COR 5 , C 1 -C 4 -alkyl and C 1 -C 4 -haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R b , which is/are selected from halogen, NO 2 , CN, C0 2 R 4 , COR 5 , C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -cycloalkyl-C 1 -C 4 -alkyl and C 1 -C 4 -haloalkyl, with it also being possible for two radicals R b which are bonded to adjacent C atoms of Ar to be together C 3 -C 4 -alkylene; R 1 is hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -haloalkyl, C 3 -C 6 -cycloalkyl, C 3 -C 6 -cycloalkyl-C 1 -C 4 -alkyl, C 1 -C 4 -hydroxyalkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl, C 3 -C 4 -alkenyl or C 3 -C 4 -alkynyl; with the radicals n, R 1 , R 2 , R 3 , R 4 and R 5 having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 10 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D 3 receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.
摘要翻译：本发明涉及通式（I）的N - [（哌嗪基）杂芳基]芳基磺酰胺化合物，其中Q是具有1或2个N原子作为环成员的二价，6元杂芳族基团，并且任选地带有一个或两个取代基R a彼此独立地选自卤素，CN，NO 2，CO 2 R 4，COR 5，C 1 -C 4烷基和C 1 -C 4卤代烷基; Ar是苯基或6元杂芳族基，其具有1或2个N原子作为环成员，并且任选地带有一个或两个选自卤素，NO 2，CN，CO 2 R 4， COR 5，C 1 -C 6 - 烷基，C 2 -C 6 - 烯基，C 2 -C 6 - 炔基，C 3 -C 6 - 环烷基，C 3 -C 6 - 环烷基-C 1 -C 4烷基和C 1 -C 4卤代烷基，对于与Ar的相邻C原子键合在一起为C 3 -C 4亚烷基的两个基团R b是可能的; R 1是氢，C 1 -C 4烷基，C 1 -C 4卤代烷基，C 3 -C 6环烷基，C 3 -C 6环烷基-C 1 -C 4烷基，C 1 -C 4羟烷基，C 1 -C 4烷氧基-C 1 C 1-4 - 烷基，C 3 -C 4 - 烯基或C 3 -C 4 - 炔基; 具有如专利权利要求中给出的含义的基团n，R 1，R 2，R 3，R 4和R 5与N-氧化物和生理上耐受的酸添加这些化合物的盐和包含至少一种如权利要求1至10中任一项所述的N - [（哌嗪基）杂芳基]芳基磺酰胺化合物和/或至少一种I和/或N的生理上耐受的酸加成盐的药物组合物氧化物，其中适当地与生理上可接受的载体和/或辅助物质一起用于治疗对由多巴胺D3受体拮抗剂或激动剂影响的疾病，特别是用于治疗中枢神经系统疾病和肾功能紊乱。

4. 发明申请

WO2005058328A1 TETRAHYDROBENZAZEPINES AND THEIR USE IN THE MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：四氢苯并噻嗪及其在多巴胺D3受体调节中的应用
公开(公告)号：WO2005058328A1
公开(公告)日：2005-06-30
申请号：PCT/EP2004/014428
申请日：2004-12-17
申请人： ABBOTT GMBH & CO. KG , BRAJE, Wilfried , HAUPT, Andreas , LUBISCH, Wilfried , GRANDEL, Roland , DRESCHER, Karla , GENESTE, Hervé , UNGER, Liliane , SAUER, Daryl, R.
发明人： BRAJE, Wilfried , HAUPT, Andreas , LUBISCH, Wilfried , GRANDEL, Roland , DRESCHER, Karla , GENESTE, Hervé , UNGER, Liliane , SAUER, Daryl, R.
IPC分类号： A61K31/55
CPC分类号： C07D223/16 , C07D409/12
摘要： The invention relates to tetrahydrobenzazepines of the general formula (I) in which the variables Ar, A, B, Y, R 1 and R 2 have the meanings indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula (I), the physically tolerated acid addition salt of (I), the N-oxide of compound of the formula (I) and/or the physically tolerated acid addition salts of the N-oxides of (I), and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.
摘要翻译：本发明涉及通式（I）的四氢苯并吖庚因，其中变量Ar，A，B，Y，R 1和R 2具有权利要求1中所示的含义，以及这些的N-氧化物化合物，这些化合物的生理上耐受的酸加成盐和N-氧化物的生理上耐受的酸加成盐。本发明还涉及药物组合物，其包含至少一种式（I）的四氢苯并氮杂化合物，（I）的物理耐受的酸加成盐，式（I）化合物的N-氧化物和/或物理（I）的N-氧化物的耐受的酸加成盐，并且还涉及使用根据本发明的化合物治疗有益于多巴胺D3受体拮抗剂或多巴胺D3激动剂的病症。根据本发明的化合物优选可用于治疗中枢神经系统疾病如精神分裂症和抑郁症以及治疗肾功能障碍。

5. 发明申请

WO2006040180A1 AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的氨基甲酸替代双相芳族化合物
公开(公告)号：WO2006040180A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011093
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07C317/34 , C07D209/14 , C07D209/62 , C07D235/14 , A61K31/136 , A61P25/00 , A61K31/145 , A61K31/403 , A61K31/407 , A61K31/4174
CPC分类号： C07D471/04 , C07D209/14 , C07D209/62 , C07D235/14
摘要： The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula (I) wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; X is a covalent bond or N-R 2 , CHR 2 , CHR 2 CH 2 , N or C-R 2 ; Y is N-R 2a , CHR 2a , CHR 2a CH 2 or CHR 2a CH 2 CH 2 ; is a single bond or a double bond; E is CH 2 or NR 3 ; R 1 is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -alkenyl, R 2 and R 2a each independently are H, CH 3 , CH 2 F, CHF 2 or CF 3 or R 1a and R 2 or R 1a and R 2a together are (CH 2 ) n with n being 1, 2 or 3; R 3 is H or C 1 -C 4 -alkyl; R 4 and R 5 independently of each other are H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl or C 1 -C 4 -alkoxy or may form, together with N, a 4-, 5- or 6-membered saturated or unsaturated ring; R 6 and R 7 independently of each other are H or halogen; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）的氨基甲基取代的双环芳族化合物，其中Ar是选自苯基，5-或6-元C-结合的杂芳族基团的环状基团，其包含作为环成员1,2 或3个彼此独立地选自O，S和N的杂原子和稠合于饱和或不饱和的5-或6-元碳环或杂环的苯环，其中杂环包含作为环成员1， 2或3个选自N，O和S的杂原子和/或1,2或3个含杂原子的基团，各自独立地选自NR 8，其中R 8是H， C 1 -C 4 - 亚烷基，氟化C 1 -C 4 - 烷基，C 1 -C 1-4烷基，C 1 -C 4烷基，C 1 -C 4 - 其中环状基团Ar可以带有1个碳原子的烷基羰基或氟化C 1 -C 4 - 烷基羰基， 2或3个取代基R a a，其中变量R a a具有在声明和说明书; X是共价键或NR 2，CHR 2，CHR 2 CH 2，N或CR ^{2 ; Y是NR 2a，CHR 2，H 2，CH 2，CH 2或CHR 2 O 2， CH _{2 CH _{2 ; 是单键或双键; E是CH 2或NR 3; R 1是H，C 1 -C 4 - 烷基，C 3 -C 4 - C 3 -C 4 - 环烷基甲基，C 3 -C 4 - 亚烷基，C 3 -C 4 - 环烷基，C 3 -C 4 - 氟化C 1 -C 4 - 亚烷基，氟化C 3 -C 4 - 环烷基，氟化C _{-C _{3 - 烷基羰基; R 1a是H，C 1 -C 4 - 烷基，C 3 -C 4烷基， C 3 -C 4 - 亚烷基，氟化C 1 -C 4 - 亚烷基，C 3 -C 4 - 氟化C 3 -C 4 - 环烷基，氟化C 3 -C 4 - 亚烯基，R SUP > 2和R 2a各自独立地为H，CH 3，CH 2，F，CHF 2， >或CF 3或R 1a和R 2或R 1a和R 2a和R 2b 一起是n为1,2或3的（CH 2）2 n。 R 3是H或C 1 -C 4 - 烷基; R 4和R 5彼此独立地为H，C 1 -C 4 - 烷基，氟化C C 1 -C 4 - 烷基或C 1 -C 4 - 烷氧基，或者可以与N， 4-，5-或6-元饱和或不饱和环; R 6和R 7彼此独立地为H或卤素; 及其生理上耐受的酸加成盐。本发明还涉及式（I）化合物或其药学上可接受的盐在制备用于治疗易受多巴胺D3受体配体治疗的医学疾病的药物组合物中的用途。}}}}}

6. 发明申请

WO2006040179A1 AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节障碍的氨基甲醛化合物
公开(公告)号：WO2006040179A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011092
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07C311/29 , C07C311/21 , C07D213/76 , C07D207/09 , C07C317/22 , C07C317/14 , A61K31/18 , A61K31/44 , A61P25/18
CPC分类号： C07D213/76 , C07C311/21 , C07C311/29 , C07C2601/02 , C07D207/09
摘要： The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C l -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, or R 1a and R 2 together are (CH 2 ) n with n being 2, 3 or 4, or R 1a and R 2a together are (CH 2 ) n with n being 2, 3 or 4; R 2 and R 2a are independently of each other H, C 1 -C 4 -alkyl or fluorinated C 1 -C 4 -alkyl or R 2a and R 2 together are (CH 2 ) m with m being 1, 2, 3, 4 or 5; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, fluorine, C 1 -C 4 -alkyl and fluorinated C 1 -C 4 -alkyl or together form a moiety (CH 2 ) p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D 3 receptor ligand.
摘要翻译：本发明涉及式（I）的芳族化合物，其中Ar是苯基或芳族5-或6-元C-结合杂芳族基团，其中Ar可以携带1个基团R 1

7. 发明申请

WO2006040176A1 AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译：适用于治疗多巴胺D3受体调节紊乱的化学物质
公开(公告)号：WO2006040176A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011089
申请日：2005-10-14
申请人： ABBOTT GMBH & CO. KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland
IPC分类号： C07D209/52 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/00 , A61P25/28
CPC分类号： C07D401/12 , C07D209/52 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to a compound of the formula (I) wherein R 1 is H, C 1 -C 6 -alkyl which may be substituted by C 3 -C 6 -cycloalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a ; wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中R

8. 发明申请

WO2006040178A1 ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR 审中-公开
标题翻译： ARYLSULFONYLMETHYL或ARYLSULFANAMID替代芳香化合物适用于治疗多巴胺D3受体制剂的病症
公开(公告)号：WO2006040178A1
公开(公告)日：2006-04-20
申请号：PCT/EP2005/011091
申请日：2005-10-14
申请人： ABBOTT GMBH & CO.KG , DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe
发明人： DRESCHER, Karla , HAUPT, Andreas , UNGER, Liliane , TURNER, Sean, C. , BRAJE, Wilfried , GRANDEL, Roland , HENRY, Christophe
IPC分类号： C07D311/04 , C07D215/38 , C07C211/19 , A61K31/13 , A61K31/47 , A61K31/35 , A61P25/16
CPC分类号： C07C311/21 , C07C311/29 , C07C311/44 , C07C2601/02 , C07C2602/10 , C07D207/10 , C07D211/10 , C07D215/38 , C07D239/84 , C07D263/32 , C07D277/82 , C07D311/04 , C07D413/04 , C07D491/04
摘要： The present invention relates to aromatic compounds of the formula (I), wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; Y is O, S, -CH=N-, -CH=CH- or -N=CH-; A is CH 2i O or S; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C4-cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C,-C 3 -alkylcarbonyl; R 1a is H, C 2 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, or R 1a and R 2 together are (CH 2 ) n with n being 2 or 3, or R 1 a and R 2a together are (CH 2 ) n with n being 2 or 3; R 2 and R 2a are independently of each other H, CH 3 , CH 2 F, CHF 2 or CF 3 ; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, C 1 -C 2 -alkyl and fluorinated C 1 -C 2 -alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）的芳族化合物，其中Ar是苯基或芳族5-或6-元C-结合的杂芳族基团，其中Ar可以携带1个基团R 1

9. 发明申请

WO2007118899A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR 审中-公开
标题翻译：用于治疗反应调节SEROTONIN 5HT6受体的疾病的异环芳烃
公开(公告)号：WO2007118899A1
公开(公告)日：2007-10-25
申请号：PCT/EP2007/053807
申请日：2007-04-18
申请人： ABBOTT GMBH & CO. KG , GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane , PLATA, Dan
发明人： GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane , PLATA, Dan
IPC分类号： C07D205/04 , C07D207/09 , C07D211/28 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K31/445 , A61K31/397 , A61K31/4025 , A61P25/18
CPC分类号： C07D207/09 , C07D205/04 , C07D211/28 , C07D401/12 , C07D403/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
摘要： The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT 6 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中变量具有权利要求书和说明书中给出的含义。本发明还涉及式（I）化合物或其药学上可接受的盐在制备用于治疗易受5HT 6受体配体治疗的医学疾病的药物中的用途。

10. 发明申请

WO2007118900A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR 审中-公开
标题翻译：用于治疗响应调节SEROTONIN 5HT6受体的疾病的异种化合物
公开(公告)号：WO2007118900A1
公开(公告)日：2007-10-25
申请号：PCT/EP2007/053808
申请日：2007-04-18
申请人： ABBOTT GMBH & CO. KG , GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane
发明人： GRANDEL, Roland , BRAJE, Wilfried Martin , HAUPT, Andreas , TURNER, Sean Colm , LANGE, Udo , DRESCHER, Karla , UNGER, Liliane
IPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , A61K31/4545 , A61P25/00
CPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT 6 receptor ligand.
摘要翻译：本发明涉及式（I）化合物，其中变量具有权利要求书和说明书中给出的含义。本发明还涉及式（I）化合物或其药学上可接受的盐在制备用于治疗易受5HT 6受体配体治疗的医学疾病的药物中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式